Oncology Clinical Trials

We have the EXPERIENCE You Need to Manage Your Oncology Clinical Trial

With specific expertise in oncology, cardiovascular, and CNS, among other therapeutic areas, Clinipace Worldwide has managed over 90 contract research projects conducted globally at almost 3,000 sites with 100,000 patients.

Clinipace offers unmatched expertise in providing emerging and mid-tier biopharmaceutical and medical device firms technology-driven contract research services. With more than 80% of our clinical operations staff having seven or more years of relevant industry and trial experience we provide exceptional operational, regulatory, and scientific guidance and oversight to your trial.

Our oncology clinical trial experience includes managing a wide range of multi-phase global oncology projects, including:

  • Phase 1 Cancer Chemotherapy Induced Anemia


  • Phase 1 Solid Tumor Targeted Therapy


  • Phase 1 and Phase 2 Solid Tumor


  • Phase 2 Ovarian, Breast, and Lung Cancer (Formal Feasibility Study)


  • Phase 2 Non-Hodgkins lymphoma


  • Phase 2 Renal Cell Carcinoma (Formal Feasibility Study)


  • Phase 3 Pancreatic Cancer


  • Phase 4 T-cell Lymphoma


  • Phase 4 Lymphoblastic Leukemia

How Can We Help You?

Oncology clinical trials are a high stakes game in the CRO business.  Given that over 500,000 Americans die each year of cancer, it is the second most common cause of death in the US and it afflicts a large number of age groups.  Unlike other therapeutic trials, oncology trials are more sensitive in nature and require specific clinical expertise to properly manage.  Most participants are required to have already undergone front and even second lines of therapy and only if these have failed are they eligible for the experimental and toxic drugs required in oncology trials. 

Given the high stakes involved, running a successful oncology trial can result in high returns.  Before embarking on an oncology trial, teaming with the right CRO can reduce trial complexity and result in a more efficient trial.  There are many special considerations you should take into account, including:

  • How to determine the best eligibility criteria and stick to it


  • How to choose the right investigator to increase enrollment (this often means going outside of the US to get the best participants for your trial)


  • Why you need to consider the role of technology in reducing trial complexity and running a more efficient trial:

    • - Partnering with a CRO to monitor which sites are getting patients on board and whether they meet eligibility requirements

    - Partnering with a CRO to keep down prices through licensed technology

    - Increasing trial efficiency through centralized data, standardized processes, branded methodology, and integrated site management with monitoring and regulatory aspects

    - Collecting and analyzing real-time data to track study results and implement corrective action, if required

  • How to develop and track patient treatment plans

Clinipace Oncology Trial News

Wednesday, May 5, 2010
Vaccinogen Selects Clinipace Worldwide to Manage Global Phase 3b Clinical Trial

Vaccinogen, a biotech company with more than thirty years experience researching how to combat cancer using the body's own immune system, has selected Clinipace to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II colon cancer.Clinipace's technology-driven service model and global oncology experience drive efficiencies for phase 3b trial. Study Stats: Phase 3b; 550 patients; 47 global sites; US, South America, Europe

Thursday, April 27, 2010
Clinipace Worldwide to Manage Clinical Trials for Four New Clients

Following industry trends crediting oncology products as one of the largest drivers of clinical development growth, Clinipace Worldwide has been granted two oncology-related trials, one Phase 2 and one Phase 3 trial.

Monday, November 9, 2009
Clinipace Acquires Worldwide Clinical Research, Inc.

Combined, the companies have managed over 90 contract research projects conducted globally at almost 3,000 sites with 100,000 patients. With specific expertise in oncology, among other therapeutic areas, the company will offer fully-integrated technology-based clinical research solutions and services to growth-oriented and mid-tier biopharmaceutical and medical device firms.

Wednesday, May 06, 2009
Clinipace Expands its Team of Clinical Development Experts

William McCulloch, M.B. (MD), F.R.C.P., F.F.P.M. will advise the Oncology and Immunology team. Since 1984, Dr. McCulloch has been a prolific researcher in the pharmaceutical industry who has contributed to over a dozen IND and NDA submissions, 24 + scientific abstracts, published 14 peer-reviewed articles and contributed three chapters to Oncology-related treatment books. Prior to that, he practiced medicine for seven years in the U.K.

What Our Customers Have To Say


"Vaccinogen selected Clinipace Worldwide for its global clinical trial due to its strength and experience managing phase 3 international oncology trials. We are confident Clinipace's therapeutic and operations experts, along with its technology platform, will enable us to centrally manage a very complex protocol with some very unique requirements."

Michael G. Hanna, Jr., Ph.D., Founder, Chairman and CEO of Vaccinogen